FREMONT, Calif.--(BUSINESS WIRE)--DiscoveRx Corporation today announced that it has expanded its cell-based PathHunterTM ß-Arrestin assays to include 45 validated cell products, each expressing a different Gi, Gs or Gq –coupled receptor. By offering cells, GPCR expression vectors, and custom services for all GPCR classes—without a license fee—DiscoveRx now has the broadest, most accessible product portfolio for measuring direct activation of GPCR signaling.
